Clinical Trials

MainTitle

HIV Disclosure and Medication Adherence, a Pilot Study (RSAD-VIH-11)

This study has been completed
Sponsor
Policlinique Médicale Universitaire

Collaborator
Centre Hospitalier Universitaire Vaudois
Swiss HIV Cohort Study

Information provided by (Responsible Party)
Marie Schneider, Policlinique Médicale Universitaire

ClinicalTrials.gov Identifier
NCT01621412

First received: May 31, 2012
Last updated: December 21, 2015
Last Verified: December 2015
History of Changes
Purpose

Purpose

The investigators believe that disclosure of HIV status could influence medication adherence. If disclosure leads to social support, adherence could be improved. This study purpose is to assess correlation between disclosure and medication adherence, and to describe people whose HIV status has been disclosed to.

Condition
HIV Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: HIV Disclosure and Medication Adherence, a Pilot Study

Further study details as provided by Marie Schneider, Policlinique Médicale Universitaire:

Primary Outcome Measures

  • Patient Adherence [ Time Frame: 30 days before survey ]
    Electronic monitoring of adherence during 30 days before survey
Secondary Outcome Measures:
  • Patient Adherence [ Time Frame: 90 days before survey ]
    Electronic monitoring of adherence during 90 days before survey

Enrollment: 120
Study Start Date: April 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)

Detailed Description:

Pharmacists administer a questionnaire to each consecutive subject taking part in the adherence-enhancing program at the pharmacy of the Department of Ambulatory Care And Community Medicine in Lausanne. This questionnaire assesses disclosure, response to disclosure, and living situation.
Adherence is measured by electronic monitoring and pill count.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  
Sampling Method: Non-Probability Sample  

Study Population

Patients enrolled in the adherence-enhancing program at ther pharmacy of Department of Ambulatory Care and Community Medicine in Lausanne

Criteria

Inclusion Criteria:

  • HIV Infection
  • Enrolled in the adherence-enhancing program


Exclusion Criteria:
  • Inclusion visit
  • Not french or english speaker

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01621412

Locations

Switzerland
Policlinique Médicale Universitaire
Lausanne, Vaud, Switzerland, 1011

Sponsors and Collaborators

Policlinique Médicale Universitaire
Centre Hospitalier Universitaire Vaudois
Swiss HIV Cohort Study

Investigators

Principal Investigator: Marie-Paule Schneider, PhD Policlinique Médicale Universitaire
Principal Investigator: Aurélie Gertsch, PhD-Student Policlinique Médicale Universitaire
Study Chair: Olivier Bugnon, Professor Policlinique Médicale Universitaire
Study Chair: Matthias Cavassini, MD Centre Hospitalier Universitaire Vaudois
More Information

More Information


Responsible Party: Marie Schneider, Pharmacist, PhD, Policlinique Médicale Universitaire  
ClinicalTrials.gov Identifier: NCT01621412   History of Changes  
Other Study ID Numbers: RSAD-VIH-2011  
Study First Received: May 31, 2012  
Last Updated: December 21, 2015  

Keywords provided by Marie Schneider, Policlinique Médicale Universitaire:

Medication Adherence
HIV infection
Disclosure

Additional relevant MeSH terms:
HIV Infections

ClinicalTrials.gov processed this data on December 15, 2017
This information is provided by ClinicalTrials.gov.